{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:08:31Z","timestamp":1790762911490,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangsu Provincial Health Commission key project","award":["K2024072"],"award-info":[{"award-number":["K2024072"]}]},{"name":"Research Project of Nantong Health Commission","award":["MS2024025"],"award-info":[{"award-number":["MS2024025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00797-1","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:44:09Z","timestamp":1779893049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrative single-cell and bulk analyses reveal ATF4-associated immune suppression and WNT\/\u03b2-catenin signaling in osteosarcoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiaomin","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"797_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pbiomolbio.2025.07.001","volume":"197","author":"X Wang","year":"2025","unstructured":"Wang X, et al. Advances and challenges in the treatment of osteosarcoma. Prog Biophys Mol Biol. 2025;197:60\u201374.","journal-title":"Prog Biophys Mol Biol"},{"key":"797_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.12.024","volume":"500","author":"C Chen","year":"2021","unstructured":"Chen C, et al. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1\u201310.","journal-title":"Cancer Lett"},{"issue":"1","key":"797_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X. Advances on immunotherapy for osteosarcoma. Mol Cancer. 2024;23(1):192.","journal-title":"Mol Cancer"},{"key":"797_CR4","doi-asserted-by":"publisher","first-page":"1584450","DOI":"10.3389\/fimmu.2025.1584450","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, et al. Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights. Front Immunol. 2025;16:1584450.","journal-title":"Front Immunol"},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"907550","DOI":"10.3389\/fimmu.2022.907550","volume":"13","author":"T Zhu","year":"2022","unstructured":"Zhu T, et al. Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications. Front Immunol. 2022;13:907550.","journal-title":"Front Immunol"},{"key":"797_CR6","doi-asserted-by":"publisher","first-page":"709210","DOI":"10.3389\/fonc.2021.709210","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma. Front Oncol. 2021;11:709210.","journal-title":"Front Oncol"},{"issue":"1","key":"797_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-024-01598-7","volume":"17","author":"X Zheng","year":"2024","unstructured":"Zheng X, et al. A single-cell and spatially resolved atlas of human osteosarcomas. J Hematol Oncol. 2024;17(1):71.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"797_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1023\/A:1023633704132","volume":"8","author":"SP Persengiev","year":"2003","unstructured":"Persengiev SP, Green MR. The role of ATF\/CREB family members in cell growth, survival and apoptosis. Apoptosis. 2003;8(3):225\u20138.","journal-title":"Apoptosis"},{"issue":"4","key":"797_CR9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00204-024-03681-x","volume":"98","author":"H Tang","year":"2024","unstructured":"Tang H, et al. ATF4 in cellular stress, ferroptosis, and cancer. Arch Toxicol. 2024;98(4):1025\u201341.","journal-title":"Arch Toxicol"},{"issue":"7","key":"797_CR10","doi-asserted-by":"publisher","first-page":"112724","DOI":"10.1016\/j.celrep.2023.112724","volume":"42","author":"JKC Kre\u00df","year":"2023","unstructured":"Kre\u00df JKC, et al. The integrated stress response effector ATF4 is an obligatory metabolic activator of NRF2. Cell Rep. 2023;42(7):112724.","journal-title":"Cell Rep"},{"issue":"7","key":"797_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2174\/0109298665314658240712051206","volume":"31","author":"M Wang","year":"2024","unstructured":"Wang M, et al. MicroRNA-605-3p Inhibited the Growth and Chemoresistance of Osteosarcoma Cells via Negatively Modulating RAF1. Protein Pept Lett. 2024;31(7):559\u201368.","journal-title":"Protein Pept Lett"},{"key":"797_CR12","doi-asserted-by":"publisher","first-page":"e210823220109","DOI":"10.2174\/1874467217666230821142839","volume":"17","author":"S Wang","year":"2024","unstructured":"Wang S, et al. The Targeted Therapies for Osteosarcoma via Six Major Pathways. Curr Mol Pharmacol. 2024;17:e210823220109.","journal-title":"Curr Mol Pharmacol"},{"issue":"9","key":"797_CR13","doi-asserted-by":"publisher","first-page":"101728","DOI":"10.1016\/j.xcrm.2024.101728","volume":"5","author":"Y Zou","year":"2024","unstructured":"Zou Y, et al. Targeting NAT10 inhibits osteosarcoma progression via ATF4\/ASNS-mediated asparagine biosynthesis. Cell Rep Med. 2024;5(9):101728.","journal-title":"Cell Rep Med"},{"issue":"9","key":"797_CR14","doi-asserted-by":"publisher","first-page":"101228","DOI":"10.1016\/j.jpha.2025.101228","volume":"15","author":"S Qin","year":"2025","unstructured":"Qin S, Kong H, Jiang L. ZFP36 promotes ferroptosis and mitochondrial dysfunction and inhibits malignant progression in osteosarcoma by regulating the E2F1\/ATF4 axis. J Pharm Anal. 2025;15(9):101228.","journal-title":"J Pharm Anal"},{"issue":"10","key":"797_CR15","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/j.immuni.2025.09.003","volume":"58","author":"CDM Alicea Pauneto","year":"2025","unstructured":"Alicea Pauneto CDM, et al. Intra-tumoral hypoxia promotes CD8(+) T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity. 2025;58(10):2489\u2013e25048.","journal-title":"Immunity"},{"issue":"10","key":"797_CR16","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, et al. WNT\/\u03b2-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019;25(10):3074\u201383.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"797_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169(6):985\u201399.","journal-title":"Cell"},{"key":"797_CR18","doi-asserted-by":"publisher","first-page":"1182307","DOI":"10.3389\/fimmu.2023.1182307","volume":"14","author":"H He","year":"2023","unstructured":"He H, et al. Combined analysis of single-cell and bulk RNA sequencing reveals the expression patterns of circadian rhythm disruption in the immune microenvironment of Alzheimer\u2019s disease. Front Immunol. 2023;14:1182307.","journal-title":"Front Immunol"},{"key":"797_CR19","doi-asserted-by":"publisher","first-page":"1579822","DOI":"10.3389\/fimmu.2025.1579822","volume":"16","author":"Z Han","year":"2025","unstructured":"Han Z, Chen G, Wang D. Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies. Front Immunol. 2025;16:1579822.","journal-title":"Front Immunol"},{"key":"797_CR20","doi-asserted-by":"publisher","first-page":"104575","DOI":"10.1016\/j.critrevonc.2024.104575","volume":"206","author":"E Adewuyi","year":"2025","unstructured":"Adewuyi E, et al. Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements. Crit Rev Oncol Hematol. 2025;206:104575.","journal-title":"Crit Rev Oncol Hematol"},{"key":"797_CR21","doi-asserted-by":"crossref","unstructured":"Park JA, Cheung NV. Promise and Challenges of T Cell Immunotherapy for Osteosarcoma. Int J Mol Sci, 2023;24(15).","DOI":"10.3390\/ijms241512520"},{"issue":"1","key":"797_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12929-024-00999-7","volume":"31","author":"C Wu","year":"2024","unstructured":"Wu C, et al. Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways. J Biomed Sci. 2024;31(1):4.","journal-title":"J Biomed Sci"},{"key":"797_CR23","doi-asserted-by":"publisher","first-page":"1112253","DOI":"10.3389\/fnmol.2023.1112253","volume":"16","author":"G Neill","year":"2023","unstructured":"Neill G, Masson GR. A stay of execution: ATF4 regulation and potential outcomes for the integrated stress response. Front Mol Neurosci. 2023;16:1112253.","journal-title":"Front Mol Neurosci"},{"issue":"7","key":"797_CR24","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1053\/j.gastro.2024.05.009","volume":"167","author":"G Malnassy","year":"2024","unstructured":"Malnassy G, et al. The Integrated Stress Response in Pancreatic Development, Tissue Homeostasis, and Cancer. Gastroenterology. 2024;167(7):1292\u2013306.","journal-title":"Gastroenterology"},{"issue":"10","key":"797_CR25","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, et al. The integrated stress response. EMBO Rep. 2016;17(10):1374\u201395.","journal-title":"EMBO Rep"},{"key":"797_CR26","doi-asserted-by":"crossref","unstructured":"Costa-Mattioli M, Walter P. The integrated stress response: From mechanism to disease. Science, 2020;368(6489).","DOI":"10.1126\/science.aat5314"},{"issue":"6","key":"797_CR27","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.18632\/oncotarget.6940","volume":"7","author":"H Zeng","year":"2016","unstructured":"Zeng H, et al. Crosstalk between ATF4 and MTA1\/HDAC1 promotes osteosarcoma progression. Oncotarget. 2016;7(6):7329\u201342.","journal-title":"Oncotarget"},{"issue":"4","key":"797_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00262-022-03286-2","volume":"72","author":"Z Lu","year":"2023","unstructured":"Lu Z, et al. Induction of the activating transcription factor-4 in the intratumoral CD8\u2009+\u2009T cells sustains their viability and anti-tumor activities. Cancer Immunol Immunother. 2023;72(4):815\u201326.","journal-title":"Cancer Immunol Immunother"},{"issue":"7559","key":"797_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231\u20135.","journal-title":"Nature"},{"key":"797_CR30","doi-asserted-by":"publisher","first-page":"155346","DOI":"10.1016\/j.prp.2024.155346","volume":"259","author":"S Fuloria","year":"2024","unstructured":"Fuloria S, et al. Targeting the Wnt\/\u03b2-catenin cascade in osteosarcoma: The potential of ncRNAs as biomarkers and therapeutics. Pathol Res Pract. 2024;259:155346.","journal-title":"Pathol Res Pract"},{"key":"797_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.","journal-title":"BMC Bioinformatics"},{"issue":"W1","key":"797_CR32","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"797_CR33","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/bioinformatics\/btv313","volume":"31","author":"M Yoo","year":"2015","unstructured":"Yoo M, et al. DSigDB: drug signatures database for gene set analysis. Bioinformatics. 2015;31(18):3069\u201371.","journal-title":"Bioinformatics"},{"issue":"4","key":"797_CR34","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3892\/or.2015.3766","volume":"33","author":"Z Li","year":"2015","unstructured":"Li Z, et al. Niclosamide inhibits the proliferation of human osteosarcoma cell lines by inducing apoptosis and cell cycle arrest. Oncol Rep. 2015;33(4):1763\u20138.","journal-title":"Oncol Rep"},{"key":"797_CR35","doi-asserted-by":"crossref","unstructured":"Yi Y et al. Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt-Axin2-Snail Cascade. Cancers (Basel), 2021;13(18).","DOI":"10.3390\/cancers13184630"},{"issue":"2","key":"797_CR36","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdr151","volume":"23","author":"G Grignani","year":"2012","unstructured":"Grignani G, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508\u201316.","journal-title":"Ann Oncol"},{"issue":"1","key":"797_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","volume":"16","author":"G Grignani","year":"2015","unstructured":"Grignani G, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98\u2013107.","journal-title":"Lancet Oncol"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00797-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:47:26Z","timestamp":1784857646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00797-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00797-1","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"130"}}